DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines

AstraZeneca

Status: Completed

Conditions: LDL Cholesterol; Observational; Crestor, Rosuvastatin; Diabetes Mellitus Type 2

Study type: Observational

Funder types: Industry

Identifiers

NCT00233649

NL401017

Details and patient eligibility

About

The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diabetes Mellitus Type 2, LDL-C > 2,5 mmol/l, no cholesterol lowering medication used last 3 months, starts with Crestor 10 mg, permission to use patient data by AZ